# QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors

> **NCT04898543** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **ImmunityBio, Inc.** · enrollment: 50 (estimated)

## Conditions studied

- Metastatic Solid Tumor

## Interventions

- **BIOLOGICAL:** M-CENK, Suspension for Infusion, Cryopreserved (M-CENK) (Cohort 2 part B)
- **BIOLOGICAL:** N-803 (Cohort 2 part B)
- **OTHER:** Apheresis collection of MNCs (part A)

## Key facts

- **NCT ID:** NCT04898543
- **Lead sponsor:** ImmunityBio, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-06-21
- **Primary completion:** 2026-05-31
- **Final completion:** 2026-05-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-12-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04898543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04898543, "QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04898543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*